首页> 外文期刊>Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus >Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer
【24h】

Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer

机译:自膨式金属食管支架在新辅助化疗治疗可切除食管癌中的安全性和有效性

获取原文
获取原文并翻译 | 示例
           

摘要

Patients with esophageal cancer may present with dysphagia and weight loss. Resectable lesions require consideration of neoadjuvant chemotherapy, which improves survival but have side effects, which compound already poor intake. Prevention of malnutrition has historically required interventions such as surgical jejunostomy or percutaneous endoscopic gastrostomy, which carry associated morbidity. With established roles in palliation, self-expanding removable metal stents (SERMS) may provide an alternative intervention in resectable disease. We sought to evaluate outcomes from our unit's introduction of SERMS in dysphagic patients prior to esophagectomy. All dysphagic patients presenting with esophageal cancer and considered for curative surgery between April 2006 and November 2008 were offered preoperative treatment of dysphagia with SERMS during neoadjuvant chemotherapy. Baseline and preoperative outcomes assessed included dysphagia score and nutritional markers. Sixteen patients underwent esophageal stenting during neoadjuvant therapy of whom 7/16 (44%) were female with mean age 63 (53-76). In 12/16 (75%), tumors were located in the lower one third of the esophagus. There was a significant fall in mean dysphagia score from 2.5 (range 1-4) to 1.1 (range 0-3) immediately preoperatively. There was no significant change in serum albumin, weight, or body mass index. Stent-related morbidity occurred in 4/16 (25%) patients and stomach migration occurred in 7/16 (43.8%). All were resolved endoscopically and there was no stent-related mortality. Of 10/16 (62.5%) patients ultimately progressing to esophagectomy, 30-day mortality was 6.3%. Anastomotic leak occurred in one patient (10%) and R1 resection rate was 20%. SERMS are a safe and effective intervention in dysphagic patients undergoing neoadjuvant chemotherapy for esophageal cancer. Complications are minor and readily treatable with endoscopy. Objective parameters suggest nutritional status is maintained and symptoms are improved. SERMS do not appear to compromise resection.
机译:食道癌患者可能会出现吞咽困难和体重减轻。可切除的病灶需要考虑新辅助化疗,这可以提高生存率,但有副作用,这已经使摄入不足。预防营养不良在历史上一直需要采取干预措施,例如手术空肠造口术或经皮内窥镜胃造口术,它们都会带来相关的发病率。自体扩张性可移动金属支架(SERMS)在缓解中已确立作用,可能为可切除疾病提供替代性干预措施。我们试图评估在食管切除术前吞咽困难的患者中,本部门引入SERMS的结果。在2006年4月至2008年11月期间,所有考虑到食管癌且考虑进行根治性手术的吞咽困难患者在新辅助化疗期间均接受了SERMS吞咽困难的术前治疗。评估的基线和术前结果包括吞咽困难评分和营养指标。新辅助治疗期间有16例患者接受了食管支架置入术,其中7/16(44%)是女性,平均年龄63岁(53-76)。在12/16(75%)的患者中,肿瘤位于食道的下三分之一。术前平均吞咽困难评分从2.5(1-4范围)显着下降到1.1(0-3范围)。血清白蛋白,体重或体重指数无明显变化。支架相关的发病率发生在4/16(25%)患者中,胃部迁移发生在7/16(43.8%)中。所有这些均在内镜下解决,没有支架相关的死亡率。在最终进展为食管切除术的10/16(62.5%)患者中,30天死亡率为6.3%。一名患者发生吻合口漏(10%),R1切除率为20%。 SERMS是为食管癌行新辅助化疗的吞咽困难患者的安全有效干预措施。并发症较小,可通过内窥镜检查轻松治疗。客观参数表明营养状况得到维持,症状得到改善。 SERMS似乎不影响切除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号